Inebilizumab for neuromyelitis optica spectrum disorder: a systematic review
HTA Journal · 04.08.2026 · 1 (1) · 7-18
DOI: 10.67516/htaj.26.1.7 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift HTA Journal, online erschienen am 04.08.2026. Verfasst von Bruna Carolina de Araújo und 10 weiteren Autor:innen. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, immune-mediated inflammatory disease of the central nervous system associated with severe disability and a relapsing course. Inebilizumab, a humanized anti-CD19 monoclonal antibody, was developed to prevent relapses in NMOSD. This systematic review aims to evaluate the efficacy and safety of inebilizumab in adults with NMOSD, regardless of aquaporin-4 immunoglobulin G (AQP4-IgG) serostatus.
Methods
We conducted a systematic review of randomized controlled trials (RCTs) in accordance with the Cochrane Handbook and reported using PRISMA 2020. We searched MEDLINE, EMBASE, CENTRAL, LILACS, ClinicalTrials.gov, WHO-ICTRP, and additional sources without restrictions. Eligible trials compared inebilizumab with placebo, no treatment, or active comparators. Outcomes included relapse, disability, visual acuity, NMOSD-related hospitalizations, and adverse events. Risk of bias was assessed using the Cochrane tool, and the certainty of evidence using the GRADE approach.
Results
We included two RCTs: one ongoing (NCT07010302) and one published trial (N-MOmentum; n = 230) comparing inebilizumab 300 mg with placebo. Inebilizumab probably reduces time to relapse (hazard ratio 0.27; 95% confidence interval [CI] 0.15–0.50; moderate certainty of evidence), NMOSD-related hospitalizations (risk ratio [RR] 0.40; 95% CI 0.17–0.97; moderate certainty of evidence), and disability worsening (RR 0.46; 95% CI 0.28–0.76; moderate certainty of evidence). Effects on serious adverse events are uncertain (very low evidence certainty). We observed little or no difference in the risk of any adverse events and in visual acuity (low evidence certainty).
Conclusions
Inebilizumab probably reduces time to relapse, disability worsening, and disease-related hospitalizations in NMOSD. However, uncertainty remains regarding safety outcomes, and further trials with longer follow-up are required to better characterize the long-term efficacy and safety.
Zitieren
APA
Araújo, B. C. D., Cruz, C. M., Latorraca, C. D. O. C., Stein, C., Toledo, I. P. D., Almeida, M. M. G. D., Parreira, P. D. C. S., Pacheco, R. L., Silva, R. B., Colpani, V., & Riera, R. (2026). Inebilizumab for neuromyelitis optica spectrum disorder: a systematic review. HTA Journal, 1(1), 7-18. https://doi.org/10.67516/htaj.26.1.7
Vancouver
Araújo BCD, Cruz CM, Latorraca CDOC, Stein C, Toledo IPD, Almeida MMGD, et al. Inebilizumab for neuromyelitis optica spectrum disorder: a systematic review. HTA Journal. 2026;1(1):7-18. doi:10.67516/htaj.26.1.7
BibTeX
@article{Arajo2026,
author = {Araújo, Bruna Carolina de and Cruz, Camila Monteiro and Latorraca, Carolina de Oliveira Cruz and Stein, Cinara and Toledo, Isabela Porto de and Almeida, Mylena Maria Guedes de and Parreira, Patrícia do Carmo Silva and Pacheco, Rafael Leite and Silva, Roberta Borges and Colpani, Verônica and Riera, Rachel},
title = {Inebilizumab for neuromyelitis optica spectrum disorder: a systematic review},
journal = {HTA Journal},
year = {2026},
volume = {1},
number = {1},
pages = {7--18},
doi = {10.67516/htaj.26.1.7}
}
EUVIMED